Digital chatbot program for inherited cancer genetic testing in young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Young adults ages 18–39 with a history of cancer are randomized to either standard telehealth genetic counseling or an enhanced eHealth program that uses the Genetic Journey chatbot for pre-test education, with genetic testing and result disclosure conducted remotely. The primary goals are to see if the chatbot increases uptake of genetic counseling and uptake of genetic testing. Secondary aims compare short-term and long-term cognitive (knowledge), affective (distress), behavioral (screening and family communication) outcomes, and costs to determine non-inferiority. Exploratory analyses will examine moderators of uptake and outcomes and identify barriers and facilitators to implementing the digital delivery model.

Why it matters

Who can join: the full rules

* PATIENTS: Age ≥ 18 years and ≤ 39 years at the time of enrollment
* PATIENTS: AYA cancer patients and survivors. This includes patients at any stage of diagnosis (e.g., newly diagnosed, in treatment, in survivorship) and a cancer diagnosis (including pediatric cancers) at any age ≤ 39 years old. Given targeted therapies for BRCA+ and microsatellite instability (MSI)-high/Lynch Syndrome patients and benefit to relatives, patients with metastatic cancer are included. Any history of cancer, regardless of being in treatment or not
* PATIENTS: Language: In order to complete the mandatory patient-completed measures and receive genetic education and counseling, participants must be able to speak and read English or Spanish
* PATIENTS: No known diagnosis of dementia or cognitive impairment. Persons with impaired decision-making capacity are ineligible as they need to be able to understand genetic test results, its implications for the patient and family, and explain genetic test results to their family members
* PATIENTS: No persons with a known psychiatric or documented developmental disorder that affects cognitive or emotional functions to the extent that the capacity for judgment and reason is significantly diminished, such that they cannot participate based on the judgment of the treating physician
* PATIENTS: Participants must meet National Comprehensive Cancer Network (NCCN) guidelines for genetic testing assessment provided by Penn Telegenetics by the Eligibility Verification Assessment (EVA) chatbot, or paper forms and genetic counselor's review
* NON-PATIENT PARTICIPANT: Non-patient participants eligible for this study include: oncology providers, members of the care team and clinic staff, genetic counselors, and insurers (i.e., people who work in financial services and/or for insurance companies) who participate in oncology care among AYA in community for this study
* NON-PATIENT PARTICIPANT: Age ≥ 18 years
* NON-PATIENT PARTICIPANT: Non-patient participants must be able to speak and read English or Spanish in order to participate in the key informant interviews

Where it's running

• Anchorage Associates in Radiation Medicine
  Anchorage, Alaska, United States Recruiting
• Alaska Breast Care and Surgery LLC
  Anchorage, Alaska, United States Recruiting
• Alaska Oncology and Hematology LLC
  Anchorage, Alaska, United States Recruiting
• Alaska Women's Cancer Care
  Anchorage, Alaska, United States Recruiting
• Katmai Oncology Group
  Anchorage, Alaska, United States Recruiting
• Providence Alaska Medical Center
  Anchorage, Alaska, United States Recruiting

+277 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Rachel Wills
• Email: cancercontrolprotocols@alliancenctn.org
• Phone: 773-702-9171

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding a targeted cancer drug to standard therapy for untreated CLL/SLL

  This trial tests whether adding sonrotoclax to zanubrutinib helps people with untreated CLL/SLL live longer without the disease getting worse.

  Recruiting at 259 sites Phase 3 Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 260 other locations · NCT07321652

• Targeted post-surgery radiation plus standard therapy for NSCLC with remaining nodal cancer

  This phase II trial tests whether adding intensity-modulated post-operative radiation therapy to standard chemotherapy or immunotherapy helps people with non-small cell lung cancer and remaining lymph node cancer after surgery.

  Recruiting at 121 sites Phase 2 Alliance for Clinical Trials in Oncology · Jonesboro, Arkansas and 124 other locations · NCT07293247

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

• Vor a sid en ib + temozolomide after radiation for IDH-mutant astrocytoma (grade 3)

  This phase 3 trial tests whether adding vorasidenib to the usual temozolomide after radiation helps people with newly diagnosed IDH-mutant astrocytoma (grade 3).

  Recruiting at 176 sites Phase 3 Alliance for Clinical Trials in Oncology · Phoenix, Arizona and 176 other locations · NCT07215910

• Testing Different Dosing Schedules of Lutetium-177Lu PSMA RLT in Advanced Prostate Cancer

  This trial tests if spacing out Lutetium-177Lu PSMA RLT doses adapts to the patient and improves quality of life without shortening life in men with advanced, hormone-resistant prostate cancer.

  Recruiting at 105 sites Phase 3 Alliance for Clinical Trials in Oncology · Anchorage, Alaska and 141 other locations · NCT07200830

• Family genetics: who shares test results with relatives

  This study tests whether letting patients share genetic results with their relatives is as good as doctors sharing the results to help first-degree relatives get genetic testing for hereditary cancer risk.

  Recruiting at 362 sites Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 364 other locations · NCT07143487

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.